Cogent Biosciences (COGT) is poised for two product launches later this year after the FDA granted priority review for its marketing application for its lead candidate, bezuclastini, for a rare form ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The facilities span cities from ...

Ulysses Management exited its entire stake in Cogent Communications last quarter by selling 335,982 shares. The shares were previously worth about $12.9 million. Prior to the sale, this position ...

Cogent is a Tier 1 internet backbone provider — the highway system underneath the internet. When data travels across the country or around the world, it often rides Cogent’s all-optical IP network, ...

Cogent Security raised $42M in Series A funding led by Bain Capital Ventures. Cogent Security uses agentic AI to automate vulnerability detection and remediation. This fund will support product ...

Cogent Security on Wednesday announced raising $42 million in Series A funding to develop autonomous AI agents for vulnerability remediation. The funding was led by Bain Capital Ventures, with ...

First Turn Management acquired 824,283 shares of Cogent Biosciences in the fourth quarter. The quarter-end value for the new stake rose by $29.28 million, reflecting both trading activity and price ...

Cogent Biosciences stock more than doubled on Monday after the biotech company reported positive trial results for an investigational cancer drug.

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next year after what Leerink said was “the first positive trial in this disease in ...

Cogent Biosciences’ stock rose 119% after the Phase III data was announced. Image credit: T. Schneider / Shutterstock.com. Cogent Biosciences’ stock has soared after its lead asset, bezuclastinib plus ...

Cogent Biosciences has cleared another phase 3 hurdle for lead asset bezuclastinib, teeing up an approval submission for a form of gastrointestinal cancer in the first half of next year. The tyrosine ...